{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Long JP"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["e253455"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11976493"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(4)"],"pubmed_abstract":["<h4>Importance</h4>Cytokine storm (CS) is a hyperinflammatory syndrome causing multiorgan dysfunction and high mortality, especially in patients with malignant hematologic neoplasms. Triggers include malignant neoplasm-associated hemophagocytic lymphohistiocytosis (MN-HLH), cytokine release syndrome from chimeric antigen receptor T-cell therapy (CAR-T CRS), and COVID-19, but the underlying mechanisms of inflammation and their impact on outcomes are poorly understood.<h4>Objective</h4>To delineate the inflammatory patterns characterizing different CS etiologies and their association with clinical outcomes.<h4>Design, setting, and participants</h4>This retrospective cohort study was conducted at the MD Anderson Cancer Center in Houston, Texas, between March 1, 2020, and November 20, 2022, us"],"journal":["JAMA network open"],"pubmed_title":["Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy."],"pmcid":["PMC11976493"],"funding_grant_id":["P30 CA016672","UL1 TR003167"],"pubmed_authors":["Castillo LEM","Rayson C K","Samir U","Ahmed S","Anai K","Mulanovich V","Edelkamp P","Phillip T","Teny M J","Jay J P","Daver NG","John C","Knafl M","Juan C","James C Y","Lucas R","David J","Nicholas P","Mark K","Sabitha P","Christopher G","John W","Cristhiam RH","Ishwaria S","Paul A S","Maria G","Hussein T","Chihara D","Flowers CR","Andrew F","Kate H","Long JP","Lee A","Daniel P S","Benju V","Woodman SE","Tejo M","Thomas A A","Pratibha B","John CT","Catherine M C","Chingyi Y","Elizabeth M B","Westin J","Myrna G","Mayoora M","Mark C W","Scott Eric W","Drew G","Al-Zaki A","Kiran K B","Bouthaina D","Iyer SP","Vinod R","Neelapu S","Lionel AC","Michael C","Caroline C","Hannah C B","Hiba D","Ashley A","Mary M","Paul E","Kenna R S","Craig S O","Bilja S","Chien K","Data-Driven Determinants for COVID-19 Discovery Effort (D3CODE) Team","J Jack L","Mary D","Max C W","Emily Y","Trey K","Jennifer L","Khawaja F","Sanu A","Jillian G","Nastoupil LJ","Strati P","Kevin M D","Jeff J","Anastasia T","Stephanie S","Kevin W M","Steven Z","Carol W","Nair R","Janna A B","Sarah F","Giulio D","Lessley J S","Prakash R","Katy E F","Jia W","Futreal A","Benjamin M","Sanjay S","Priyadharshini P","Kristy B","Gregory R B","Joseph N","Manzano JG"],"additional_accession":[]},"is_claimable":false,"name":"Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy.","description":"<h4>Importance</h4>Cytokine storm (CS) is a hyperinflammatory syndrome causing multiorgan dysfunction and high mortality, especially in patients with malignant hematologic neoplasms. Triggers include malignant neoplasm-associated hemophagocytic lymphohistiocytosis (MN-HLH), cytokine release syndrome from chimeric antigen receptor T-cell therapy (CAR-T CRS), and COVID-19, but the underlying mechanisms of inflammation and their impact on outcomes are poorly understood.<h4>Objective</h4>To delineate the inflammatory patterns characterizing different CS etiologies and their association with clinical outcomes.<h4>Design, setting, and participants</h4>This retrospective cohort study was conducted at the MD Anderson Cancer Center in Houston, Texas, between March 1, 2020, and November 20, 2022, us","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-06T17:42:25.666Z","creation":"2025-07-12T03:04:24.7Z"},"accession":"S-EPMC11976493","cross_references":{"pubmed":["40193078"],"doi":["10.1001/jamanetworkopen.2025.3455"]}}